Xiu zhen Tong

Summary

Country: China

Publications

  1. pmc Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia
    Meifeng Zhou
    Department of Hematology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou, Guangdong, 510080, China
    Diagn Pathol 10:147. 2015
  2. doi request reprint Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
    Xiu zhen Tong
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, China
    Biochem Pharmacol 83:586-97. 2012
  3. ncbi request reprint [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]
    Xiu zhen Tong
    Department of Hematology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou 510080, China
    Zhonghua Zhong Liu Za Zhi 28:545-8. 2006
  4. ncbi request reprint [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]
    Xiu zhen Tong
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 26:914-8. 2007
  5. ncbi request reprint [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:620-3. 2003
  6. doi request reprint Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia
    Fang Wang
    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat Sen University, Guangzhou, 510060, China
    Eur J Cancer 47:1990-9. 2011
  7. ncbi request reprint [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong 510080, P R China
    Ai Zheng 23:1696-9. 2004
  8. ncbi request reprint [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma]
    Juan Li
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 27:429-34. 2008
  9. ncbi request reprint [Expression of CD117 antigen on multiple myeloma and its significance]
    Juan Li
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 23:951-4. 2004
  10. ncbi request reprint [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 23:430-4. 2004

Collaborators

Detail Information

Publications16

  1. pmc Downregulated Poly-C binding protein-1 is a novel predictor associated with poor prognosis in Acute Myeloid Leukemia
    Meifeng Zhou
    Department of Hematology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou, Guangdong, 510080, China
    Diagn Pathol 10:147. 2015
    ..However, the underlying biological effect of PCBP1 in cancers, including acute myeloid leukemia (AML), still remains elusive. The purpose of this study was to examine the expression and clinical outcome of PCBP1in acute myeloid leukemia...
  2. doi request reprint Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
    Xiu zhen Tong
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, China
    Biochem Pharmacol 83:586-97. 2012
    ..These findings should be useful for the combination of apatinib and chemotherapeutic agents in the clinic...
  3. ncbi request reprint [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]
    Xiu zhen Tong
    Department of Hematology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou 510080, China
    Zhonghua Zhong Liu Za Zhi 28:545-8. 2006
    ..To retrospectively analyze the curative effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia patients (CML)...
  4. ncbi request reprint [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia]
    Xiu zhen Tong
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 26:914-8. 2007
    ..This study was to analyze the efficacy and toxicity of intravenous Bu and cyclophosphamide (Cy) conditioning before allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for leukemia...
  5. ncbi request reprint [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:620-3. 2003
    ..This study was conducted to compare the effectiveness and side-effects of two conditioning regimens in allogeneic hematopoietic stem cell transplantation (allo-HSCT)...
  6. doi request reprint Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia
    Fang Wang
    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat Sen University, Guangzhou, 510060, China
    Eur J Cancer 47:1990-9. 2011
    ..Functional polymorphisms of the ABCG2 gene may contribute to individual variability in drug response and the prognosis of patients...
  7. ncbi request reprint [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong 510080, P R China
    Ai Zheng 23:1696-9. 2004
    ..Chronic myeloid leukemia (CML) in blast phase is refractory with a poor prognosis. This study was to evaluate efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on CML in blast phase...
  8. ncbi request reprint [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma]
    Juan Li
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 27:429-34. 2008
    ..This study was to explore the medical effects and side effects of bortezomib combined dexamethasone in treating newly diagnosed and relapsed or refractory MM, and evaluate the safety of this regimen in the patients with renal impairment...
  9. ncbi request reprint [Expression of CD117 antigen on multiple myeloma and its significance]
    Juan Li
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 23:951-4. 2004
    ....
  10. ncbi request reprint [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia]
    Guo Cai Zhang
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong, 510080, PR China
    Ai Zheng 23:430-4. 2004
    ..The objective of the study was to observe whether combination of the two drugs could improve efficacy or in contrary accentuate adverse reactions...
  11. ncbi request reprint [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]
    Shao Kai Luo
    Department of Hematology, The First Affiliated Hospital, Sun Yat Sen University, Guangzhou, Guangdong 510080, P R China
    Ai Zheng 24:1518-21. 2005
    ....
  12. ncbi request reprint [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma]
    Juan Li
    Department of Hematology, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou 510080, China
    Zhonghua Yi Xue Za Zhi 88:2140-3. 2008
    ..To explore the proportion, clinical and laboratory features, chemotherapy responses and long term survival of different kinds of newly diagnosed multiple myeloma (MM) in China...
  13. doi request reprint Up-regulation of ABCB1/P-glycoprotein by escaping promoter hypermethylation indicates poor prognosis in hematologic malignancy patients with and without bone marrow transplantation
    Cheng Jun Shi
    State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Leuk Res 35:73-9. 2011
    ..In addition, MDR1 in K562 cells elevated significantly after 5-Aza-dC treatment. In summary, MDR1 promoter hypomethylation conferred its up-regulation and indicated poor prognosis in patients with and without BMT...
  14. ncbi request reprint [Inhibitory effect of apatinib on HL-60 cell proliferation and its mechanism]
    Shu Liang
    Department of Hematology, Yat sen University, Guangzhou 510060, China
    Nan Fang Yi Ke Da Xue Xue Bao 31:871-4. 2011
    ..To investigate the effect of apatinib, a small-molecule vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, on the proliferation of human acute myeloid leukemia HL-60 cells and explore the possible mechanism...
  15. ncbi request reprint [Establishment of an animal model of oral mucositis induced by conditioning regimen of haematopoietic stem cell transplantation]
    Xiao Bing Chen
    Department of Oral Medicine, Guanghua School of Stomatology, Sun Yat Sen University, Guangzhou 510055, China
    Zhonghua Kou Qiang Yi Xue Za Zhi 42:672-6. 2007
    ..To establish a rat model of oral mucositis (OM) induced by busulfan and cyclophosphamide (BUCY) conditioning regimen of hematopoietic stem cell transplantation (HSCT)...
  16. doi request reprint Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
    Chun Ling Dai
    State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat Sen University, Guangzhou 510060, China
    Cancer Lett 279:74-83. 2009
    ..Overall, we conclude that sunitinib reverses ABCG2-mediated MDR through inhibiting the drug efflux function of ABCG2. These findings may be useful for cancer combinational therapy with sunitinib in the clinic...